EverSource Wealth Advisors LLC Raises Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

EverSource Wealth Advisors LLC boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 38.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,572 shares of the company’s stock after purchasing an additional 710 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in CRISPR Therapeutics were worth $147,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in CRSP. Capital International Investors boosted its stake in CRISPR Therapeutics by 27.8% in the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after purchasing an additional 1,702,624 shares in the last quarter. SR One Capital Management LP purchased a new position in CRISPR Therapeutics in the first quarter worth about $71,496,000. Norges Bank bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth approximately $38,661,000. Avoro Capital Advisors LLC purchased a new stake in shares of CRISPR Therapeutics during the first quarter valued at approximately $28,599,000. Finally, PBCay One RSC Ltd purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $10,329,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Up 1.2 %

CRSP stock opened at $46.49 on Friday. The business’s 50-day moving average price is $49.43 and its 200-day moving average price is $56.23. The stock has a market cap of $3.95 billion, a P/E ratio of -17.09 and a beta of 1.68. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $12.31 million. The business’s quarterly revenue was down 99.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.98) EPS. On average, equities research analysts expect that CRISPR Therapeutics AG will post -5.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRSP has been the topic of several analyst reports. Barclays lowered their price objective on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Royal Bank of Canada reduced their price objective on CRISPR Therapeutics from $66.00 to $60.00 and set a “sector perform” rating for the company in a report on Tuesday, August 6th. Chardan Capital lowered their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, Guggenheim reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $75.63.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.